28.37
6.69%
1.78
Dopo l'orario di chiusura:
28.35
-0.02
-0.07%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALKS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$26.59
Aprire:
$27.87
Volume 24 ore:
2.45M
Relative Volume:
1.51
Capitalizzazione di mercato:
$4.80B
Reddito:
$1.51B
Utile/perdita netta:
$333.35M
Rapporto P/E:
22.88
EPS:
1.24
Flusso di cassa netto:
$315.22M
1 W Prestazione:
+7.30%
1M Prestazione:
-2.07%
6M Prestazione:
+17.96%
1 anno Prestazione:
+14.44%
Alkermes Plc Stock (ALKS) Company Profile
Nome
Alkermes Plc
Settore
Telefono
00-353-1-772-8000
Indirizzo
CONNAUGHT HOUSE, DUBLIN 4
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2023-11-20 | Ripresa | JP Morgan | Neutral |
2023-10-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
2023-10-17 | Iniziato | UBS | Neutral |
2022-11-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2022-10-14 | Aggiornamento | BofA Securities | Underperform → Neutral |
2022-08-16 | Iniziato | Piper Sandler | Neutral |
2022-04-22 | Ripresa | Goldman | Buy |
2022-04-20 | Iniziato | Goldman | Buy |
2022-01-27 | Aggiornamento | Cantor Fitzgerald | Hold → Overweight |
2021-12-01 | Iniziato | Citigroup | Neutral |
2021-10-07 | Aggiornamento | Jefferies | Hold → Buy |
2021-09-02 | Downgrade | BofA Securities | Neutral → Underperform |
2020-10-15 | Aggiornamento | Mizuho | Neutral → Buy |
2020-07-30 | Downgrade | Goldman | Neutral → Sell |
2020-02-14 | Downgrade | BofA/Merrill | Buy → Neutral |
2020-02-14 | Reiterato | H.C. Wainwright | Neutral |
2020-02-14 | Downgrade | JP Morgan | Overweight → Neutral |
2020-02-06 | Iniziato | Mizuho | Neutral |
2020-01-31 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
2019-09-05 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
2019-07-15 | Aggiornamento | Goldman | Sell → Neutral |
2019-05-31 | Iniziato | H.C. Wainwright | Neutral |
2019-05-01 | Downgrade | Citigroup | Buy → Neutral |
2018-12-19 | Downgrade | Goldman | Neutral → Sell |
2018-12-14 | Iniziato | Wolfe Research | Underperform |
2018-12-13 | Downgrade | Credit Suisse | Outperform → Underperform |
2018-11-05 | Iniziato | Piper Jaffray | Neutral |
2018-08-07 | Iniziato | Stifel | Hold |
2018-06-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
2018-06-06 | Iniziato | B. Riley FBR, Inc. | Buy |
2018-05-16 | Aggiornamento | Citigroup | Neutral → Buy |
2018-05-11 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Alkermes Plc Borsa (ALKS) Ultime notizie
Vanguard Group Inc's Recent Transaction in Alkermes PLC Shares - GuruFocus.com
Alkermes (NASDAQ:ALKS) Shares Gap UpTime to Buy? - MarketBeat
Alkermes raised to buy by Stifel on increased confidence for ALKS2680 - MSN
Alkermes raised to buy by Stifel on increased confidence for ALKS2680 (NASDAQ:ALKS) - Seeking Alpha
Alkermes (NASDAQ:ALKS) Upgraded by Stifel Nicolaus to Buy Rating - MarketBeat
A Glimpse Into The Expert Outlook On Alkermes Through 9 Analysts - Benzinga
Stifel raises Alkermes target to $36, upgrades to buy By Investing.com - Investing.com Australia
Stifel raises Alkermes target to $36, upgrades to buy - Investing.com India
DekaBank Deutsche Girozentrale Lowers Stock Holdings in Alkermes plc (NASDAQ:ALKS) - MarketBeat
(ALKS) Proactive Strategies - Stock Traders Daily
Short Interest in Alkermes plc (NASDAQ:ALKS) Drops By 7.9% - MarketBeat
Alkermes plc (NASDAQ:ALKS) Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
Alkermes holds steady stock target with neutral rating amid royalty segment dip - Investing.com
Alkermes holds steady stock target with neutral rating amid royalty segment dip By Investing.com - Investing.com South Africa
Alkermes's SWOT analysis: innovative pipeline drives CNS stock's future - Investing.com
Alkermes Eyes Completion of Phase 2 Narcolepsy Studies in 2025 - Sleep Review
Goldman Sachs keeps Alkermes stock buy-rated ahead of milestone readouts, trims PT - Investing.com Canada
Piper Sandler cuts Alkermes stock target, keeps Overweight rating By Investing.com - Investing.com Australia
Leerink maintains Alkermes stock rating with $28 target amid financial projections - Investing.com Australia
Leerink maintains Alkermes stock rating with $28 target amid financial projections By Investing.com - Investing.com South Africa
Alkermes (NASDAQ:ALKS) PT Lowered to $30.00 - MarketBeat
Piper Sandler cuts Alkermes stock target, keeps Overweight rating - Investing.com
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down - MSN
Alkermes' Q3 Earnings & Revenues Fall Shy Of Estimates, Stock Down - Barchart
Alkermes' (ALKS) Overweight Rating Reiterated at Piper Sandler - MarketBeat
Alkermes plc (NASDAQ:ALKS) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Alkermes Plc reports solid Q3 growth, eyes future expansion - Investing.com
Alkermes Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Alkermes PLC (ALKS) Q3 2024 Earnings Call Highlights: Strong Pro - GuruFocus.com
Substance Abuse Treatment Market to Witness Massive Growth (2024-2031)| Allergan PLC, Alkermes, Noramco. - openPR
Alkermes PLC (ALKS) Q3 2024 Earnings Call Highlights: Strong Proprietary Product Growth and ... - Yahoo Finance
Alkermes: Q3 Earnings Snapshot - mySA
Alkermes' Q3 Proprietary Sales Soar 18% - The Motley Fool
Alkermes (NASDAQ:ALKS) Shares Gap DownHere's Why - MarketBeat
Moody Aldrich Partners LLC Has $2.38 Million Stock Position in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Alkermes plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Fetal Alcohol Spectrum Disorder Treatment Market Overall Study - openPR
Alkermes PLC Q3 2024 Earnings: EPS of $0.56 Beats Estimates, Rev - GuruFocus.com
Alkermes (NASDAQ:ALKS) Updates FY 2024 Earnings Guidance - MarketBeat
Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates - Yahoo Finance
Alkermes plc Reports Third Quarter 2024 Financial Results - PR Newswire
Alkermes' SWOT analysis: undervalued neuro-innovator stock faces pivotal phase - Investing.com
Alkermes's Earnings: A Preview - Benzinga
Alkermes PLC (ALKS) Q3 2024 Earnings Report Preview: What to Exp - GuruFocus.com
Alkermes (ALKS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures - Yahoo Finance
Alkermes plc (NASDAQ:ALKS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Alkermes plc (NASDAQ:ALKS) Stock Holdings Increased by Vontobel Holding Ltd. - MarketBeat
Learn to Evaluate (ALKS) using the Charts - Stock Traders Daily
ALKSAlkermes Inc. plc Latest Stock News & Market Updates - StockTitan
Alkermes (ALKS) to Release Quarterly Earnings on Thursday - MarketBeat
Alkermes Plc Azioni (ALKS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alkermes Plc Azioni (ALKS) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Parisi Samuel Joseph | VP, Finance (Interim PAO) |
Feb 27 '24 |
Sale |
29.65 |
2,559 |
75,874 |
7,717 |
LAURENCIN CATO T | Director |
Feb 15 '24 |
Option Exercise |
22.52 |
2,690 |
60,579 |
17,859 |
LAURENCIN CATO T | Director |
Feb 15 '24 |
Sale |
31.85 |
2,690 |
85,676 |
15,169 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):